BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed – Yahoo Finance

Strategist Michael Antonelli joins Jared Blikre to break down the Fed decision and more at 2 P.M. ET Wednesday.
No Lower Age Restriction for Treatment
Japan Accounts for Approximately Half of the 1,500 Patient Opportunity in APAC Region
SAN RAFAEL, Calif., June 21, 2022 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted approval of the registration of VOXZOGO® (vosoritide) for injection, indicated for the treatment of achondroplasia in children of all ages, whose growth plates are not closed.  Voxzogo, a modified C-type natriuretic peptide (CNP), directly targets the underlying pathophysiology of achondroplasia by down regulating fibroblast growth factor receptor 3 (FGFR3) signaling and consequently promoting endochondral bone formation.
BioMarin Announces Approval of VOXZOGO in Japan for Children of all ages
“We are delighted to offer children in Japan of all ages with achondroplasia access to a treatment option that addresses the underlying genetic mechanism of the condition,” said Jean-Jacques Bienaimé, Chairman and CEO of BioMarin. “CNP was discovered as a natural regulator of bone growth in Japan in 1990 so we are especially proud to be able to offer a therapeutic choice there.  We look forward to nurturing our partnerships with advocates and the achondroplasia community in Japan and beyond.”
The MHLW in Japan based its decision on the outcomes of a global Phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Voxzogo and the long-term extension of this Phase 3 study as well as data from patients participating in a Phase 2 randomized, double-Blind, placebo-controlled clinical trial evaluating the safety and efficacy of Voxzogo in infants and young children with achondroplasia, age 0 to < 60 months.
In 2021, Voxzogo received approvals in the United States, Europe and Brazil.
About Achondroplasia
Achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature, is characterized by slowing of endochondral bone growth, which results in disproportionate short stature and disordered architecture in the long bones, spine, face and base of the skull.  This condition is caused by a gain of function mutation in the fibroblast growth factor receptor 3 gene (FGFR3), a negative regulator of bone growth.  More than 80% of children with achondroplasia have parents of average stature and have the condition as the result of a spontaneous change in the gene.
Around 25% of individuals living with achondroplasia have open growth plates. The worldwide incidence rate of achondroplasia is about one in 25,000 live births.
Safety and efficacy of Voxzogo in patients with achondroplasia were assessed in one 52–week, multi–center, randomized, double–blind, placebo–controlled, Phase 3 study.  Transient decreases in blood pressure have been observed with Voxzogo. In the clinical study, 8 (13%) of 60 patients treated with Voxzogo had a total of 11 events of transient decreases in blood pressure compared to 3 (5%) of 61 patients on placebo, over a 52-week treatment period. Patients with significant cardiac or vascular disease or on anti-hypertensive medicine were excluded from the trial.  To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, fatigue and/or nausea), patients should be well hydrated and have adequate food intake prior to administration.
The most common adverse reactions, occurring in greater than or equal to 5% of patients treated with Voxzogo and at a percentage greater than placebo in the Phase 3 study are injection site reactions (including redness, itching, swelling, bruising, rash, hives, pain), vomiting, joint pain, decreased blood pressure, gastroenteritis, diarrhea, dizziness, ear pain, influenza, fatigue, seasonal allergy, and dry skin.
U.S. VOXZOGO Indication
In the United States, VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia who are 5 years of age and older with open growth plates (epiphyses).  VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company’s portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit  Information on such website is not incorporated by reference into this press release.
Forward-Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: BioMarin’s VOXZOGO development program generally, the potential market size in Japan, and APAC, and that the continued approval for this indication in the U.S. may be contingent upon the verification and description of clinical benefit in confirmatory studies.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results and timing of ongoing and possible future clinical trials of VOXZOGO; our ability to successfully manufacture Voxzogo; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning Voxzogo; the actual size of the Japanese market for VOXZOGO and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin® is a registered trademark and VOXZOGO® is a registered trademark of BioMarin Pharmaceutical Inc.

Traci McCarty
Debra Charlesworth
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455-7558
(415) 455-7451
View original content to download multimedia:
SOURCE BioMarin Pharmaceutical Inc.
Related Quotes
The government health-insurance program for seniors could have saved as much as $3.6 billion over one year if it had bought generic drugs from the pharmacy, Harvard Medical School researchers estimate.
The Chester County company is working with the India-based developer of Covaxin to bring the Covid-19 vaccine to North America.
(Reuters) -The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc’s claims that an Ohio hospital’s employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare. In a 7-2 decision authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital’s employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease.
A panel of the FDA’s outside experts voted 9-3 that Acadia Pharmaceuticals Inc’s (NASDAQ: ACAD) pimavanserin doesn’t appear to be effective at treating patients with Alzheimer’s-related psychosis. The drug, Nuplazid, is already indicated for Parkinson’s-related psychosis. Acadia tried and failed last year to get another FDA approval for Alzheimer’s psychosis. Related: Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis. "We are disappoin
Shares of Acadia Pharmaceuticals Inc. were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the company’s treatment for hallucinations and delusions associated with Alzheimer’s disease psychosis. The committee on Friday voted 9-3 that the benefits of pimavanserin do not outweigh the risks. The FDA, which is not required to follow the advice of the committee but often does, is expected to decide whether to app
The inability to stand on one leg for 10 seconds after the age of 50 could indicate an early death is on the horizon, new research suggests.
Top pharmaceutical company Eli Lilly’s (NYSE: LLY) diabetes division achieved a key milestone with the approval of Mounjaro in May for type 2 diabetes. This is a turnaround from earlier this year when the prospects of key immunology blockbuster Olumiant were dampened by Food and Drug Administration (FDA) concerns over its safety. Lilly’s strengthening outlook for its immunology treatments has the potential to shore up future revenue growth.
The Federal Trade Commission said it would consider taking action against pharmacy-benefit managers and drugmakers, saying their deals raise drug prices. The PBMs and pharma companies blame each other.
American Academy of Pediatrics issued new guidelines on safe sleeping for babies
Edgewise Therapeutics Inc (NASDAQ: EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). EDG-5506 was well-tolerated with no discontinuations or dose reductions. The most common adverse events observed at the 10 mg dose were dizziness (17%) and somnolence (17%). These were generally transient and typically observed in the first few days of dosing. All patients have subsequently been dose-escalated to 15 mg daily as per protocol. R
Dr. SarahBeth Hartlage, 36, died unexpectedly in March while at a medical conference in Florida. Here’s what happened.
The FDA, CDC authorized Pfizer and Moderna’s vaccines for kids 6 months and up. Here’s where to find vaccines for young children, possible side effects and more
Experts share their advice about isolation, masking and more if you’re still testing positive late into a COVID-19 infection.
Critics have gone after Florida Governor Ron DeSantis over his decision not to pre-order COVID-19 vaccines for children under five years old.
Age matters when it comes to taking certain medications and supplements. According to the U.S. Drug and Food Administration "As you get older, body changes can affect the way medicines are absorbed and used. For example, changes in the digestive system can affect how fast medicines enter the bloodstream. Changes in body weight can influence the amount of medicine you need to take and how long it stays in your body. The circulatory system may slow down, which can affect how fast drugs get to the
Dialysis Patient Citizens Statement Following Supreme Court Decision in Marietta Memorial Hospital v. DavitaPR NewswireWASHINGTON, June 22, 2022WASHINGTON, June 22, 2022 /PRNewswire/ — Following the United States Supreme Court decision in the case of Marietta Memorial Hospital v.
Medicare could have saved up to $3.6 billion in 2020 if it bought generic drugs at the prices paid by billionaire entrepreneur Mark Cuban’s drug company, according to a new study. The study from researchers at Brigham and Women’s Hospital in Boston, published in the journal Annals of Internal Medicine, suggests inefficiencies in the…
Leon’s positivity rate jumped past that of the state of Florida, with 20 percent of tests coming back positive for the county.
These healthy thirst-quenchers are a triple threat: refreshing, tasty, and hydrating.
U.S.-listed shares of Valneva soared 81.9% in premarket trading on Tuesday, the day after Pfizer Inc. announced a $95 million equity investment in Valneva as part of a previously established agreement aimed at developing a Lyme disease vaccine. The investment is expected to support the Phase 3 clinical trials for the Lyme disease vaccine candidate, which are set to begin in the third quarter of this year. The companies also announced other changes to the licensing agreement, including upping Val


Leave a Reply

Your email address will not be published.